Thelansis

Asthma Market Outlook Thelansis’s “Asthma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Asthma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What insights do interviewed experts p...

 Asthma represents a multifaceted clinical syndrome characterized by variable airflow obstruction, bronchial hyperresponsiveness (BHR), and cellular inflammation. The Global Initiative for Asthma (GINA) defines asthma as a heterogeneous disease primarily marked by airway inflammation. The presence of respiratory symptoms such as wheezing, shortness of breath, chest tightness, and cough, exhibiting variability over time and in intensity, alongside variable expiratory airflow limitation, constitutes the defining features of asthma. This condition results in fluctuating respiratory symptoms and variable airflow limitation, culminating in compromised activity levels, diminished quality of life, and occasional exacerbations, colloquially termed 'asthma attacks.' These exacerbations may necessitate emergency healthcare utilization and hospitalization and, in rare instances, lead to fatalities. Asthma's risk factors encompass genetic, environmental, and host-related elements. Whil...

  Asthma is a chronic inflammatory condition of the airways in which hypertrophy of bronchial smooth muscle and mucous glands with plugging of small airways with thick mucus can occur. This airway inflammation contributes to airway hyper-responsiveness, airflow limitation, and respiratory symptoms and is at the root of the disease's chronic nature. Based on the clinical features classified as mild intermittent, mild persistent, moderate persistent, or severe persistent, depending on symptom frequency and severity and lung function as assessed by forced expiratory volume in 1 second (FEV1). Depending on symptoms, signs, and functional assessment, asthma exacerbations are classified as mild, moderate, severe, and impending respiratory failure. The incidence of Asthma in the USA varies from 158 to 187 cases per 100,000 populations, and the prevalence varies between 6.7 to 8.5 across all ages. Thelansis’s “Asthma Market Outlook, Epidemiology, Competitive Landscape , an...